Most therapeutic peptides are administered by injection, typically subcutaneous (just under the skin). This is because peptides are fragile molecules that break down quickly in the digestive system, making non-injectable routes challenging. However, newer technologies are expanding the options, and today peptides can also be delivered orally, nasally, and through experimental skin patches.
Why Injection Is the Default
Peptides are short chains of amino acids, and your body treats them the same way it treats the proteins in food: it digests them. When swallowed, peptides face stomach acid with a pH as low as 1.0, followed by a gauntlet of digestive enzymes throughout the intestines. At least 15 different enzymes along the gut lining target and break apart these molecules. The result is that oral bioavailability for most peptides sits below 1%, and sometimes below 0.1%. In practical terms, almost none of the peptide you swallow reaches your bloodstream intact.
Injection bypasses all of this. A subcutaneous injection places the peptide directly into the tissue beneath the skin, where it absorbs into the bloodstream without encountering digestive enzymes. This is why insulin, growth hormone, and most other peptide therapies have historically required needles.
Subcutaneous Injection
Subcutaneous injection is by far the most common route for peptide therapies. You inject into the fatty layer just beneath the skin, pinching a one- to two-inch fold of skin and inserting the needle at an angle. The most frequently used sites are the abdomen (avoiding a two-inch radius around the belly button), the front or outer thigh, the upper buttocks, and the back of the upper arm if someone else is giving the injection.
Rotating your injection site with each dose helps prevent irritation and tissue changes at any single spot. Abdominal injections tend to be less painful than thigh injections, so if discomfort is an issue, the belly is generally the better choice. Letting a refrigerated peptide warm to room temperature for 30 to 45 minutes before injecting also reduces pain significantly. Never use a microwave or direct heat source, as high temperatures can destroy the peptide.
Common side effects at the injection site include redness, mild pain, burning, or stinging. These reactions are usually short-lived. Applying a topical numbing cream or holding an ice pack to the area for a minute before injecting can help. Hypersensitivity reactions, when they occur, typically show up within minutes to hours or within 24 to 48 hours after injection.
Reconstituting Peptides Before Injection
Many peptides ship as a freeze-dried (lyophilized) powder that you mix with bacteriostatic water before use. This reconstitution step requires clean technique: swab the vial tops with alcohol, inject the water slowly down the side of the vial, and let the powder dissolve gently without shaking. Once mixed, store the vial in the refrigerator at 2 to 8°C (roughly 36 to 46°F) and avoid freezing and thawing it repeatedly, as this degrades the peptide. If you need multiple doses from one vial, dividing the solution into smaller portions at the start can help preserve stability. Check for cloudiness or color changes before each use, as these can signal contamination or breakdown.
Intravenous and Intramuscular Routes
Some peptides are given intravenously (directly into a vein) or intramuscularly (into muscle tissue), though these routes are more common in clinical settings than for self-administration. Intravenous delivery provides the fastest onset because the peptide enters the bloodstream immediately, with peak levels reached within minutes. Intramuscular injection is slower. Studies on glucagon, for example, show that the elimination half-life after intramuscular injection is three to four times longer than after intravenous infusion (roughly 29 to 31 minutes versus 7 to 12 minutes), largely because the peptide releases gradually from the muscle tissue rather than hitting the bloodstream all at once.
The choice between these routes depends on the clinical situation. Emergency peptides like glucagon may be given intramuscularly for speed and practicality, while certain hospital-administered peptides go through an IV line for precise dosing control.
Oral Peptide Delivery
Oral delivery has long been considered the holy grail for peptide drugs because patients overwhelmingly prefer swallowing a pill over injecting themselves. The breakthrough came with oral semaglutide (Rybelsus), which became the first FDA-approved oral peptide drug. It uses a co-formulated absorption enhancer called SNAC that works through three simultaneous mechanisms: it neutralizes the acidic environment immediately around the tablet, protecting the peptide from stomach enzymes; it prevents the peptide molecules from clumping together, which would block absorption; and it temporarily increases the permeability of the stomach lining so the peptide can pass through into the bloodstream.
Even with this technology, oral peptide delivery remains inefficient compared to injection. The tablet must be taken on an empty stomach with no more than four ounces of water, and you need to wait at least 30 minutes before eating or drinking anything else. These restrictions exist because food and additional liquid interfere with the narrow window during which the absorption enhancer is active. Despite these limitations, oral semaglutide demonstrated that pill-form peptide delivery is possible, and it has opened the door for similar approaches with other peptide drugs.
Nasal Delivery
Nasal sprays offer another needle-free option for peptide administration. The nasal cavity has a thin, highly vascularized lining that can absorb small molecules relatively quickly, and it avoids the digestive system entirely. Peptides delivered this way can reach the bloodstream within minutes.
The main limitation is absorption efficiency. For many peptides, nasal bioavailability without an enhancer is below 1%, similar to oral delivery. Glucagon delivered nasally, for instance, achieved less than 30% of the bioavailability seen with intramuscular injection in clinical studies. Newer permeation enhancers are improving these numbers. Research on sugar-based absorption enhancers has shown that for some smaller peptides, nasal delivery with an enhancer can approach the bioavailability of intravenous delivery. There’s a consistent pattern in the data: the smaller the peptide molecule, the better it absorbs through the nasal lining. Molecules above about 30 kilodaltons (relatively large peptides and small proteins) see diminishing returns.
Nasal peptide delivery is already in clinical use for certain applications, including some formulations of desmopressin and calcitonin, and it is particularly attractive for situations requiring fast onset without the need for a needle.
Microneedle Patches
Microneedle patches represent a newer approach that blurs the line between injection and transdermal delivery. These small adhesive patches contain arrays of tiny needles, often less than a millimeter long, that painlessly penetrate just the outermost layer of skin. The peptide is either coated on the needle tips, embedded in dissolvable needle material, or released through the micro-channels the needles create.
Animal studies have produced promising results. Dissolving microneedle patches applied to skin for just 10 minutes dissolved roughly 65% of their needle tips and deposited their payload to a depth of 150 to 200 micrometers. In insulin delivery experiments, microneedle patches lowered blood glucose in diabetic rats by as much as 80%, though the response was slower than a standard subcutaneous injection: blood glucose reached its lowest point at about five hours with the patch versus 1.5 hours with injection. Hydrogel-forming patches delivered 60% of their insulin load over 12 hours, suggesting potential for sustained, steady-state delivery that could reduce the number of daily doses.
These patches are still largely in development for peptide therapeutics, but they offer a compelling future for people who need regular peptide dosing without daily injections.
How Half-Life Shapes Dosing Frequency
Regardless of the delivery route, how often you take a peptide depends heavily on how quickly your body clears it. Natural peptides tend to have very short half-lives in the bloodstream, sometimes just minutes. This is why pharmaceutical development has focused on engineering longer-lasting versions. Techniques like attaching a peptide to a protein found abundantly in blood (albumin) or to a fatty acid chain can extend the half-life from minutes to days or even weeks. Semaglutide, for example, is modified to bind to albumin in the bloodstream, which is what allows it to be dosed just once weekly by injection or once daily by mouth rather than multiple times per day.
Less frequent dosing directly improves the likelihood that people stick with their treatment. A weekly injection is far more manageable than a daily one, and this practical consideration drives much of the innovation in peptide drug design and delivery.